Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02167789 · ClinicalTrials.gov registry record · Phase 3
Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT Device
A Phase 3 study of Heart Failure, sponsored by LivaNova.
- Completed
- Registry status
- Phase 3
- Development phase
- 520
- Enrollment target
- 20
- Study locations
NCT02167789: Completed Phase 3 study of Heart Failure, sponsored by LivaNova.
NCT02167789 is a Phase 3 study of Heart Failure that has completed, run by LivaNova. The registered enrollment target is 520 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02167789, a Phase 3 study of Heart Failure, has completed, sponsored by LivaNova.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical investigation is a prospective, non-randomized, multi-center, pivotal trial.This trial is being performed in order to demonstrate the sensivity of the diagnostic feature "Physiological Diagnostic" (PhD).
Conditions Studied
Interventions
- DEVICE Paradym CRT 8770
Study Locations (20)
Arizona
- Dr. Haines - Kaplan, Phoenix,
- Drs. Lewis, Garg - Siegel, Phoenix,
Quebec
- Dr. Champagne, Dr. Philippon - Québec
- Drs. Thibualt, Guerra - Québec
Nantes
- Dr. Burban - Nantes
- Dr Abbey - Nantes
Massachusetts
- Drs. Jagmeet Singh, Kevin, Hiest - Boston
New York
- Drs. John Fisher, Jay Gross - Montefiore, Bronx NY
South Carolina
- Dr. Gold - Charleston
Angers
- Dr. Dupuis - Angers
Grenoble
- Dr. Defaye - Grenoble
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
What the finished NCT02167789 record still lists
NCT02167789 is an interventional study that assigns participants to a tested intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Paradym CRT 8770 is the first listed.
NCT02167789 names 20 study sites across 17 states, led by Arizona, Quebec, Nantes.
Frequently Asked Questions
What is clinical trial NCT02167789 about?
NCT02167789 is a clinical study titled "Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT Device". This clinical investigation is a prospective, non-randomized, multi-center, pivotal trial.This trial is being performed in order to demonstrate the sensivity of the diagnostic feature "Physiological Diagnostic" (PhD).
What is the current status of trial NCT02167789?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 520 participants. The study started on 2009-09. Estimated completion is 2013-06.
What conditions does trial NCT02167789 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT02167789?
The interventions under investigation include: Paradym CRT 8770 (DEVICE).
Who is sponsoring clinical trial NCT02167789?
This trial is sponsored by LivaNova, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02167789 being conducted?
This trial has 20 study locations across Arizona, Massachusetts, New York, South Carolina, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02167789's enrollment target sits among peer trials
520 98th of 397 higher than 300 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05445778 · 520 participants · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia